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ABSTRACT
Background: We investigated the association of baseline body mass index (BMI) and weight change since age 20
years with liver cancer mortality among Japanese.
Methods: The data were obtained from the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC
Study). A total of 31 018 Japanese men and 41 455 Japanese women aged 40 to 79 years who had no history of
cancer were followed from 1988 through 2009.
Results: During a median 19-year follow-up, 527 deaths from liver cancer (338 men, 189 women) were
documented. There was no association between baseline BMI and liver cancer mortality among men or men with
history of liver disease. Men without history of liver disease had multivariable hazard ratios (HR) of 1.95 (95%CI,
1.07–3.54) for BMI less than 18.5 kg/m2 and 1.65 (1.05–2.60) for BMI of 25 kg/m2 or higher, as compared with a
BMI of 21.0 to 22.9 kg/m2. BMI was positively associated with liver cancer mortality among women and women
with history of liver disease. Weight change since age 20 years was positively associated with liver cancer mortality
among women regardless of history of liver disease. Women with history of liver disease had a multivariable HRs of
1.96 (1.05–3.66) for weight gain of 5.0 to 9.9 kg and 2.31 (1.18–4.49) for weight gain of 10 kg or more, as compared
with weight change of −4.9 to 4.9 kg.
Conclusions: Both underweight (BMI <18.5 kg/m2) and overweight (BMI ≥25 kg/m2) among men without history
of liver disease, and weight gain after age 20 (weight change ≥5 kg) among women with history of liver disease, were
associated with increased mortality from liver cancer.
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INTRODUCTION
According to the World Health Organization, liver cancer
was responsible for 700 000 deaths worldwide in 2008 and
was the third leading cause of cancer death after lung cancer
(1.4 million deaths) and stomach cancer (740 000 deaths).1
Meta-analyses2 and systematic reviews3,4 reported
associations between excess body weight and higher risk of
liver cancer among both men and women. However, few
studies have examined the association of weight change with
risk of liver cancer.5,6
In a population with a high prevalence of chronic infection
with hepatitis C virus (HCV),7 it is important to determine
whether body weight and weight change are associated with
risk of liver cancer irrespective of viral infection (a major
contributor to liver cancer).8 Thus, we chose to examine these
associations in relation to the presence or absence of liver
disease.
We conducted a prospective study of the associations of
BMI at age 20 years, BMI at baseline, and weight change since
age 20 years with mortality from liver cancer in a large cohort
of Japanese men and women aged 40 to 79 years at baseline.
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METHODS
The Japan Collaborative Cohort Study for Evaluation of
Cancer Risk (JACC study) was initiated during
1988–1990.9,10 Self-administered questionnaires with items
on lifestyle and medical history of cancer, liver disease,
gallbladder disease, diabetes mellitus, other diseases, and
blood transfusion were completed by 110 588 people (46 398
men and 64 190 women) aged 40 to 79 years from 45
communities across Japan. Among them, 73 463 people
(31 321 men and 42 142 women) provided self-reported data
on weight and height at baseline and weight at age 20 years.
We excluded 303 men and 687 women with a reported history
of cancer at baseline, leaving 31 018 men and 41 455 women
for the present analysis.
Mortality surveillance was conducted systematically by
reviewing death certiﬁcates. Participants were followed-up
until death or until they moved away from their original
community, through the end of 2009 (follow-up of 4, 4, and 2
communities ﬁnished at the end of 1999, 2003, and 2008,
respectively). The median follow-up period was 19.0 years.
Underlying cause of death according to the International
Classiﬁcation of Diseases (ICD-10) was obtained centrally
from the Ministry of Health and Welfare. Death from liver
cancer was deﬁned as ICD-10 codes C22.0 to C22.9. The
present study was approved by the Ethical Committees of
Nagoya University and Osaka University.
Variables
Weight (kg) and height (m) were self-reported at baseline.
BMI was calculated as weight (kg) divided by height (m)
squared and then divided into 5 categories (<18.5, 18.5–20.9,
21.0–22.9, 23.0–24.9, and ≥25 kg/m2); a BMI of 21.0–
22.9 kg/m2 served as the reference group. Weight change
since age 20 years was calculated by subtracting weight at age
20 years from weight at baseline. Weight change was grouped
into 5 categories (≤−10, −9.9 to −5.0, −4.9 to 4.9, 5.0 to 9.9,
and ≥10 kg); stable weight (−4.9 to 4.9 kg) was used as the
reference group. We asked the subjects, “Do you have
a history of physician-diagnosed liver disease such as
hepatitis?”. Potential confounding variables were smoking
status (never, former, current smoker of <20 cigarettes per day,
and current smoker of ≥20 cigarettes per day), ethanol
consumption (never, former, current [1–22, 23–45, 46–68, and
≥69 g per day]), hours of walking (<0.5, 0.5, 0.6–0.9, and
≥1.0 h per day), hours of exercise (<1, 1–2, 3–4, and ≥5 per
week), frequency of coffee intake (seldom, 1–2 cups per
month, 1–2 cups per week, 3–4 cups per week, and almost
every day), frequency of ﬁsh intake (seldom, 1–2 times per
month, 1–2 times per week, 3–4 times per week, and almost
every day), education level (<10, 10–12, 13–15, and ≥16
years), area of residence (Hokkaido, Tohoku, Kanto, Chubu,
Kinki, Chugoku, and Kyushu regions), and histories of
diabetes mellitus, gallbladder disease, and blood transfusion.
A positive history of liver disease, with or without present
treatment, was also considered.
Statistical analyses
Sex-speciﬁc, age-adjusted means (SD) and proportions of
potential confounding factors were calculated by a general
linear model.
Cox proportional hazards models were used to calculate
sex-speciﬁc age- and multivariable-adjusted hazard ratios
(HRs) and 95% CIs for liver cancer mortality associated with
BMI at baseline, BMI at age 20, and weight change since
age 20 years. Multivariable-adjusted Cox modeling included
continuous age at baseline, smoking status, ethanol
consumption, hours of walking and exercise, frequencies of
coffee and ﬁsh intake, education level, area of residence,
and histories of diabetes mellitus, gallbladder disease, blood
transfusion, and positive history of liver disease with or
without present treatment. For the analysis of weight change,
the model was further adjusted for height (continuous) and
weight (continuous) at age 20. The P values for linear trends
were calculated by assigning the median value of each
category to corresponding individuals and treating it as a
continuous variable in the model. Testing for trends was
performed across the upper 3 categories of BMI (ie, ≥21.0 kg/
m2) and weight change (>−5 kg). Testing for overall trends
was performed across all 5 categories of BMI and weight
change. Multivariable-adjusted HRs were also calculated for
a 5-kg increment of weight change if necessary. To identify
effect modiﬁcation of the association between body weight or
weight change and risk of liver cancer, additional stratiﬁed
analyses were conducted based on the presence or absence
of history of liver disease at baseline in men and women.
Because lower body weight and weight loss could be due to
preclinical liver cancer, and higher body weight or weight gain
could be a consequence of ascites associated with liver cancer,
we excluded early deaths from liver cancer (ie, those that
occurred during the ﬁrst 10 years after baseline) to reduce
reverse causation in our analyses.
All analyses were conducted using SAS version 9.1.3
Service Pack 4 (SAS Institute, Cary, North Carolina, USA).
Two-tailed probability values of less than 0.05 were
considered to indicate statistical signiﬁcance.
RESULTS
Mean age at baseline, BMI at baseline, and weight change
since age 20 years, in men and women, were 57.2 (10.2) and
56.8 (9.8) years, 22.7 (2.8) and 23.0 (3.2) kg/m2, and 1.7 (8.9)
and 2.7 (8.5) kg, respectively (Table 1). We identiﬁed 527
deaths (338 men, 189 women) from liver cancer during
1 168 909 follow-up person-years (486 745 in men, 682 164 in
women).
There was no association between baseline BMI and
mortality from liver cancer among men or men with liver
Body Mass Index, Weight Change and Liver Cancer220
J Epidemiol 2013;23(3):219-226
disease. In contrast, among men without a history of liver
disease the association was U-shaped: as compared with a
BMI of 21.0 to 22.9 kg/m2, the multivariable HR (95% CI)
was 1.95 (1.07–3.54) among those with a BMI less than
18.5 kg/m2 and 1.65 (1.05–2.60) among those with a BMI of
25 kg/m2 or higher. BMI was positively associated with
mortality from liver cancer among women (P = 0.04 for
overall trend) and women with a history of liver disease
(P = 0.02 for overall trend), but not among women without a
history of liver disease (P = 0.23 for overall trend) (Table 2).
No associations were found for BMI at age 20 in either
sex (Table 3). Weight change since age 20 years was
positively associated with mortality from liver cancer among
women, women with a history of liver disease, and women
without a history of liver disease (P = 0.01, 0.02, and 0.03,
respectively). Among women with a history of liver disease,
weight gain of 5.0 to 9.9 kg was associated with a
multivariable HR of 1.96 (95% CI, 1.05–3.66) for mortality
from liver cancer, and weight gain of 10 kg or more was
associated with an HR of 2.31 (1.18–4.49), as compared
with women with a weight change of −4.9 to 4.9 kg. The
multivariable HRs associated with a 5-kg increment in weight
were 1.11 (1.00–1.28), 1.14 (1.00–1.30), and 1.17 (1.00–1.36)
among women, women with a history of liver disease, and
women without a history of liver disease, respectively. There
was no association between weight change and mortality from
liver cancer in men (Table 4). The results of the analyses that
excluded early deaths from liver cancer were essentially
identical. Among overweight men without a history of liver
disease the multivariable HR was 1.67 (0.90–3.12), versus a
BMI of 21.0 to 22.9 kg/m2. Analysis of the overall trend for
BMI categories among women and women with and without
a history of liver disease yielded P values of 0.009, 0.02,
and 0.06, respectively, in the multivariable model. Analysis
of overall trend for weight change in women, women with a
history of liver disease, and women without a history of liver
disease yielded P values of 0.007, 0.03, and 0.02, respectively
(data not shown in table).
DISCUSSION
In this large-scale prospective study of Japanese men and
women, we observed that overweight and underweight were
associated with liver cancer mortality in men without liver
disease and that weight change positively correlated with liver
cancer mortality in women, regardless of history of liver
disease.
Our results showing an excess risk of mortality from liver
cancer in overweight men without a history of liver disease are
in line with those from studies of men from the general
populations of East Asian countries,11 European countries,5,6
and the United States.12 Among women, we found a weak
positive association between BMI categories and liver cancer
mortality, which supports previous ﬁndings for women from
Table 1. Sex-speciﬁc, age-adjusted means and proportions in all subjects and subjects with and without a self-reported history
of liver disease at baseline (JACC study, 1988–2009)
Men Women
Total
History of liver diseasea
Total
History of liver diseasea
+ − + −
No. at risk 31018 2438 25793 41455 2304 35378
Age, years 57.2 (10.2) 58.4 (9.4) 56.6 (10.2) 56.8 (9.8) 58.9 (9.0) 56.1 (9.8)
Weight at baseline, kg 60.3 (8.8) 60.6 (9.1) 60.5 (8.8) 52.6 (7.8) 53.3 (8.5) 52.6 (7.8)
Weight at age 20, kg 58.6 (7.6) 58.4 (7.3) 58.6 (7.5) 49.9 (6.8) 49.7 (6.9) 49.9 (6.7)
Height at baseline, m 163.0 (6.6) 163.1 (6.3) 163.1 (6.6) 151.3 (5.8) 151.3 (5.7) 151.3 (5.8)
BMI at baseline, kg/m2 22.7 (2.8) 22.7 (2.9) 22.7 (2.8) 23.0 (3.2) 23.2 (3.3) 23.0 (3.1)
BMI at age 20, kg/m2 22.1 (2.8) 21.9 (2.6) 22.1 (2.7) 21.8 (3.0) 21.7 (3.0) 21.8 (3.0)
Weight change after age 20, kg 1.7 (8.9) 2.3 (9.2) 1.8 (8.7) 2.7 (8.5) 3.6 (9.1) 2.7 (8.3)
Never smoker, % 20.4 17.3 21.1 93.3 90.8 93.9
Current smoker, % 53.2 50.8 53.5 5.2 6.2 4.8
Never drinker, % 19.4 15.5 19.7 80.8 76.5 81.5
Current drinker, % 73.8 70.2 74.8 17.3 24.7 17.0
Walk 30min or more/day, % 68.6 64.3 69.1 71.5 68.8 71.7
Exercise 3 hours or more/week, % 14.9 15.4 14.6 9.9 9.2 9.9
Coffee 1 cup or more daily, % 36.6 36.5 36.1 36.1 37.0 35.1
Fish almost daily, % 1.3 1.3 1.3 1.6 1.5 1.6
College or higher education, % 18.6 21.9 18.3 10.7 12.0 10.7
History of diabetes mellitus, % 7.1 15.9 5.3 4.0 9.4 3.1
History of gallbladder disease, % 4.3 10.7 3.2 5.6 18.9 4.1
History of blood transfusion, % 9.4 19.7 7.6 10.3 20.9 9.1
Present treatment of liver disease, % — 28.8 — — 22.0 —
Abbreviation: BMI, body mass index.
aInformation on history of liver disease was missing for 2787 men and 3773 women.
Values are means (SD) or proportions.
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the general populations of the United States12 and Korea.11
The positive association between BMI and liver cancer risk in
women with a history of liver disease was in line with
previous ﬁndings in patients with liver disease, namely, that
a higher baseline BMI was predictive of incident liver
cancer.13–19
Two prospective studies investigated the association of
weight change during adulthood with liver cancer risk.5,6 A
study of 107 815 Swedish men with a small number of incident
liver cancers (n = 55) reported no association between weight
gain and risk of liver cancer, as compared with stable weight.5
Another study of 191 927 European men and women found a
positive dose-dependent association between weight change
after age 20 years and risk of incident liver cancer.6 However,
in sex-speciﬁc analysis, there was a positive association only
among men, perhaps due to the small number of incident liver
cancers among women (n = 54). Nonetheless, we found a
positive relationship between weight change and liver cancer
mortality in women, regardless of history of liver disease,
which conﬁrms previous ﬁndings among men. Because the
Table 2. Sex-speciﬁc, age- and multivariable-adjusted hazard ratios and 95% CIs for mortality from liver cancer according to
body mass index (BMI) categories at baseline (JACC study, 1988–2009)
BMI at baseline (kg/m2) P for
trenda
P for overall
trendb<18.5 18.5–20.9 21.0–22.9 23.0–24.9 ≥25.0
Men
No. at risk 1669 7116 8892 7583 5758
No. of person-years 21231 107857 140791 123112 93753
No. of deaths 32 82 88 73 63
Crude death ratec 151 76 63 59 67
Age-adjusted HR (95% CI) 1.87 (1.25–2.82) 1.15 (0.85–1.55) 1 1.01 (0.74–1.37) 1.20 (0.86–1.65) 0.33 0.21
Multivariable HR (95% CI)d 1.42 (0.93–2.15) 1.09 (0.81–1.48) 1 1.04 (0.76–1.42) 1.15 (0.83–1.60) 0.37 0.99
Men with liver disease
No. at risk 139 544 690 558 507
No. of person-years 1376 7055 9404 7940 7494
No. of deaths 13 30 39 34 22
Crude death ratec 945 425 415 428 294
Age-adjusted HR (95% CI) 1.86 (0.99–3.51) 0.94 (0.59–1.52) 1 1.06 (0.67–1.67) 0.75 (0.44–1.26) 0.27 0.09
Multivariable HR (95% CI)d 0.99 (0.51–1.95) 0.91 (0.55–1.48) 1 1.03 (0.64–1.66) 0.83 (0.48–1.44) 0.38 0.80
Men without liver disease
No. at risk 1303 5838 7396 6446 4810
No. of person-years 17660 91245 120182 107098 79876
No. of deaths 16 39 39 33 37
Crude death ratec 91 43 32 31 46
Age-adjusted HR (95% CI) 2.24 (1.25–4.03) 1.25 (0.80–1.96) 1 1.00 (0.63–1.59) 1.58 (1.01–2.48) 0.05 0.75
Multivariable HR (95% CI)d 1.95 (1.07–3.54) 1.22 (0.78–1.91) 1 1.08 (0.68–1.72) 1.65 (1.05–2.60) 0.03 0.78
Women
No. at risk 2560 8527 11094 9598 9676
No. of person-years 38047 138984 184657 159579 160898
No. of deaths 8 36 42 41 62
Crude death ratec 21 26 23 26 39
Age-adjusted HR (95% CI) 0.73 (0.34–1.57) 1.10 (0.71–1.72) 1 1.14 (0.74–1.75) 1.63 (1.10–2.41) 0.01 0.01
Multivariable HR (95% CI)d 0.74 (0.35–1.60) 1.08 (0.69–1.68) 1 1.16 (0.75–1.79) 1.42 (0.95–2.13) 0.10 0.04
Women with liver disease
No. at risk 136 448 572 527 621
No. of person-years 1722 6176 8157 7546 8749
No. of deaths 1 16 19 17 30
Crude death ratec 58 259 233 225 343
Age-adjusted HR (95% CI) 0.23 (0.03–1.73) 1.11 (0.57–2.15) 1 1.02 (0.53–1.96) 1.49 (0.84–2.66) 0.14 0.05
Multivariable HR (95% CI)d 0.23 (0.03–1.74) 1.14 (0.57–2.29) 1 1.20 (0.60–2.40) 1.72 (0.93–3.18) 0.09 0.02
Women without liver
disease
No. at risk 2121 7282 9572 8196 8207
No. of person-years 32776 121678 163208 139737 139789
No. of deaths 7 14 19 22 28
Crude death ratec 21 12 12 16 20
Age-adjusted HR (95% CI) 1.44 (0.60–3.45) 0.96 (0.48–1.92) 1 1.36 (0.74–2.52) 1.64 (0.91–2.93) 0.10 0.14
Multivariable HR (95% CI)d 1.32 (0.55–3.18) 0.97 (0.49–1.94) 1 1.33 (0.72–2.46) 1.49 (0.83–2.69) 0.27 0.23
aTest for trend refers to a baseline BMI of ≥21.0 kg/m2.
bTest for overall trend refers to a baseline BMI of <18.5 kg/m2.
cMortality rate is expressed as rate per 100000 person-years.
dMultivariable adjustment: age, smoking status, ethanol consumption, hours of walking, hours of exercise, frequencies of coffee and ﬁsh intake,
education level, area of residence, histories of diabetes mellitus, gallbladder disease, blood transfusion, and positive history of liver disease with or
without present treatment.
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numbers of deaths were relatively small in the ﬁrst 2 weight-
change groups (ie, ≤−10.0 and −5 to −9.9 kg) in the analyses of
women in the present study, we examined whether combining
the ﬁrst 2 weight-change groups would alter the results;
however, the P values were very similar for overall trend.
We found no association between weight change since age 20
years and risk of liver cancer in men.
The mechanism linking excess body weight or weight gain
during adulthood with higher mortality from liver cancer may
be mediated via progression of nonalcoholic fatty liver disease
(NAFLD), a clinicopathologic condition that encompasses a
wide spectrum of liver tissue changes, ranging from steatosis
alone to nonalcoholic steatohepatitis, advanced ﬁbrosis,
cirrhosis, and, in the most severe cases, liver cancer.20 Level
of obesity was found to be correlated with NAFLD
development: a study of 39 151 Japanese adults reported
that 12.8% of nonobese subjects (BMI <25 kg/m2), 51.4% of
overweight subjects (25 ≤ BMI < 30 kg/m2), and 80.4% of
highly obese subjects (BMI ≥30 kg/m2) had fatty liver disease,
as determined by abdominal ultrasonography.21 In addition,
Table 3. Sex-speciﬁc, age- and multivariable-adjusted hazard ratios and 95% CIs for mortality from liver cancer according to
body mass index (BMI) categories at age 20 years (JACC study, 1988–2009)
BMI at age 20 (kg/m2) P for
trenda
P for overall
trendb<18.5 18.5–20.9 21.0–22.9 23.0–24.9 ≥25.0
Men
No. at risk 1805 9180 10300 6372 3361
No. of person-years 28079 148241 164069 97587 48768
No. of deaths 14 91 115 75 43
Crude death ratec 50 61 70 77 88
Age-adjusted HR (95% CI) 0.78 (0.45–1.36) 0.99 (0.75–1.30) 1 0.96 (0.72–1.29) 1.02 (0.72–1.45) 0.92 0.65
Multivariable HR (95% CI)d 0.74 (0.42–1.29) 0.89 (0.68–1.18) 1 0.92 (0.69–1.24) 0.91 (0.64–1.31) 0.54 0.66
Men with liver disease
No. at risk 170 735 785 474 274
No. of person-years 2249 10227 11072 6248 3474
No. of deaths 8 34 48 31 17
Crude death ratec 356 332 434 496 489
Age-adjusted HR (95% CI) 0.86 (0.41–1.82) 0.83 (0.53–1.28) 1 1.02 (0.65–1.61) 0.97 (0.55–1.69) 0.98 0.49
Multivariable HR (95% CI)d 0.91 (0.42–1.97) 0.68 (0.43–1.07) 1 0.98 (0.61–1.56) 0.75 (0.41–1.35) 0.36 0.68
Men without liver disease
No. at risk 1456 7667 8625 5294 2751
No. of person-years 23539 127328 141043 83287 40864
No. of deaths 4 48 57 33 22
Crude death ratec 17 38 40 40 54
Age-adjusted HR (95% CI) 0.78 (0.45–1.36) 0.99 (0.75–1.30) 1 0.96 (0.72–1.29) 1.02 (0.72–1.45) 0.85 0.61
Multivariable HR (95% CI)d 0.50 (0.18–1.39) 1.05 (0.71–1.54) 1 0.81 (0.53–1.25) 0.98 (0.60–1.62) 0.76 0.99
Women
No. at risk 4061 12936 11996 7364 5098
No. of person-years 64811 214456 199655 122099 81143
No. of deaths 20 49 58 37 25
Crude death ratec 31 23 29 30 31
Age-adjusted HR (95% CI) 1.23 (0.74–2.05) 0.90 (0.61–1.32) 1 0.95 (0.63–1.43) 0.77 (0.48–1.23) 0.28 0.25
Multivariable HR (95% CI)d 0.98 (0.58–1.64) 0.85 (0.58–1.25) 1 0.91 (0.60–1.38) 0.73 (0.45–1.18) 0.18 0.49
Women with liver disease
No. at risk 289 721 582 410 302
No. of person-years 3746 10014 8348 6049 4192
No. of deaths 11 17 28 13 14
Crude death ratec 294 170 335 215 334
Age-adjusted HR (95% CI) 1.04 (0.52–2.10) 0.56 (0.31–1.02) 1 0.64 (0.33–1.24) 0.84 (0.44–1.60) 0.60 0.99
Multivariable HR (95% CI)d 0.91 (0.43–1.94) 0.53 (0.29–1.00) 1 0.61 (0.31–1.21) 0.75 (0.37–1.50) 0.32 0.98
Women without liver
disease
No. at risk 3337 11081 10396 6311 4253
No. of person-years 55240 188811 176982 106855 69299
No. of deaths 9 27 25 20 9
Crude death ratec 16 14 14 19 13
Age-adjusted HR (95% CI) 1.23 (0.74–2.05) 0.90 (0.61–1.32) 1 0.95 (0.63–1.43) 0.77 (0.48–1.23) 0.25 0.14
Multivariable HR (95% CI)d 1.28 (0.59–2.76) 1.24 (0.72–2.15) 1 1.22 (0.68–2.21) 0.62 (0.29–1.34) 0.30 0.13
aTest for trend refers to a baseline BMI of ≥21.0 kg/m2.
bTest for overall trend refers to a baseline BMI of <18.5 kg/m2.
cMortality rate is expressed as rate per 100000 person-years.
dMultivariable adjustment: age, smoking status, ethanol consumption, hours of walking, hours of exercise, frequencies of coffee and ﬁsh intake,
education level, area of residence, histories of diabetes mellitus, gallbladder disease, blood transfusion, and positive history of liver disease with or
without present treatment.
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weight gain during an average of 414 days was found to be an
independent risk factor for incident NAFLD in Japanese men
and women.22
Second, overweight (BMI ≥25 kg/m2) was associated with
a 5-fold risk of ﬁbrosis progression in liver during a 1-year
period among people with HCV infection,23 which suggests
that overweight increases the risk of liver cancer via
progression of liver ﬁbrosis.
Third, it is possible that overweight was confounded by
hepatitis C infection. However, according to a nested case-
control study24 of a JACC study subsample of approximately
12 000 adults, BMI tended to be inversely associated with
HCV infection. For example, among men without liver
disease, the proportion of those with HCV infection was
8.9% for a BMI less than 18.5 kg/m2, 7.3% for a BMI of 18.5
to less than 21.0 kg/m2, 6.9% for a BMI of 21.0 to less than
23.0 kg/m2, 6.7% for a BMI of 23.0 to less than 25.0 kg/m2,
and 4.7% for a BMI of 25.0 kg/m2 or higher. Thus, it is
unlikely that the excess risk of mortality from liver cancer in
adults with a BMI of 25.0 kg/m2 or higher was due to HCV
Table 4. Sex-speciﬁc, age- and multivariable-adjusted hazard ratios and 95% CIs for mortality from liver cancer according to
categories of weight change since age 20 years to baseline (JACC study, 1988–2009)
Weight change from age 20 to baseline (kg) P for
trenda
P for overall
trendb≤−10.0 −5 to −9.9 −4.9 to 4.9 5.0 to 9.9 ≥10.0
Men
No. at risk 2454 4831 12279 5666 5788
No. of person-years 30812 70268 197516 93608 94540
No. of deaths 27 76 124 55 56
Crude death ratec 88 108 63 59 59
Age-adjusted HR (95% CI) 0.94 (0.61–1.43) 1.32 (0.99–1.77) 1 1.06 (0.77–1.46) 1.09 (0.80–1.50) 0.59 0.85
Multivariable HR (95% CI)d 0.68 (0.43–1.08) 1.08 (0.80–1.46) 1 1.06 (0.77–1.47) 0.98 (0.70–1.37) 0.88 0.54
Men with liver disease
No. at risk 193 390 882 436 537
No. of person-years 1942 4895 12357 6322 7752
No. of deaths 11 29 49 23 26
Crude death ratec 566 592 397 364 335
Age-adjusted HR (95% CI) 1.09 (0.56–2.12) 1.26 (0.79–2.00) 1 1.03 (0.62–1.69) 0.97 (0.60–1.56) 0.89 0.48
Multivariable HR (95% CI)d 0.59 (0.28–1.23) 0.93 (0.56–1.54) 1 1.08 (0.64–1.81) 1.03 (0.61–1.72) 0.63 0.33
Men without liver disease
No. at risk 1908 3880 10406 4818 4781
No. of person-years 24969 58307 171105 81354 80327
No. of deaths 13 33 65 28 25
Crude death ratec 52 57 38 34 31
Age-adjusted HR (95% CI) 0.95 (0.52–1.73) 1.15 (0.75–1.76) 1 1.03 (0.66–1.61) 0.94 (0.59–1.50) 0.84 0.73
Multivariable HR (95% CI)d 0.69 (0.36–1.34) 0.98 (0.64–1.52) 1 1.08 (0.69–1.70) 1.00 (0.61–1.61) 0.95 0.52
Women
No. at risk 2269 5811 16186 8986 8203
No. of person-years 32934 92910 270774 150616 134929
No. of deaths 10 24 62 46 47
Crude death ratec 30 26 23 31 35
Age-adjusted HR (95% CI) 0.77 (0.39–1.52) 0.82 (0.51–1.32) 1 1.44 (0.98–2.10) 1.60 (1.10–2.34) 0.01 0.0006
Multivariable HR (95% CI)d 0.68 (0.34–1.40) 0.83 (0.51–1.35) 1 1.31 (0.89–1.94) 1.41 (0.94–2.11) 0.08 0.01
Women with liver disease
No. at risk 135 308 789 508 564
No. of person-years 1750 4400 11184 7488 7528
No. of deaths 3 15 21 22 22
Crude death ratec 171 341 188 294 292
Age-adjusted HR (95% CI) 0.67 (0.20–2.26) 1.56 (0.80–3.04) 1 1.64 (0.90–2.98) 1.70 (0.94–3.10) 0.06 0.11
Multivariable HR (95% CI)d 0.55 (0.15–2.03) 1.47 (0.72–3.00) 1 1.96 (1.05–3.66) 2.31 (1.18–4.49) 0.02 0.02
Women without liver
disease
No. at risk 1812 4880 14141 7720 6825
No. of person-years 27205 79851 241627 132498 116006
No. of deaths 4 6 36 22 22
Crude death ratec 15 8 15 17 19
Age-adjusted HR (95% CI) 0.54 (0.19–1.52) 0.35 (0.15–0.84) 1 1.22 (0.72–2.08) 1.36 (0.80–2.30) 0.24 0.003
Multivariable HR (95% CI)d 0.50 (0.17–1.49) 0.35 (0.15–0.85) 1 1.16 (0.68–1.99) 1.14 (0.65–2.00) 0.58 0.03
aTest for trend refers to weight change ≥−4.9 kg.
bTest for overall trend refers to weight change ≤−10.0 kg.
cMortality rate is expressed as rate per 100000 person-years.
dMultivariable adjustment: age, weight at age 20, height at age 20, smoking status, ethanol consumption, hours of walking, hours of exercise,
frequencies of coffee and ﬁsh intake, education level, area of residence, histories of diabetes mellitus, gallbladder disease, blood transfusion, and
positive history of liver disease with or without present treatment.
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infection. However, the excess risk of mortality from liver
cancer in those with a BMI less than 18.5 kg/m2 could be
confounded by HCV infection.
In the present study, men without liver disease and a
baseline BMI less than 18.5 kg/m2 had excess mortality from
liver cancer as compared with those with a BMI of 21.0
to 22.9 kg/m2, perhaps because underweight men without
liver disease were in a preclinical disease state. Indeed, in
our study the proportion of former drinkers was higher
among underweight men without liver disease than among
men with a BMI of 21.0 to 22.9 kg/m2 (10% vs 5%).
However, the associations were weaker in sensitivity analyses
that excluded deaths from liver cancer within 10 years
(n = 77) and former drinkers (n = 1277) from men without
liver disease: the multivariable HRs were 1.80 (95% CI,
0.72–4.53) and 1.86 (95% CI, 0.96–3.58), respectively.
Therefore, the increased risk of mortality from liver cancer
associated with low BMI is unlikely to be due to reverse
causation. The mechanisms responsible should be investigated
in future studies.
Our study beneﬁted from a long follow-up period and a
large population-based sample, which allowed us to examine
associations with liver cancer in narrow ranges of BMI and
weight change in both men and women. However, some
limitations of the present study should be discussed. First, the
lack of information on HCV infection, a major risk factor
for liver cancer,8 is a major limitation of the current study.
Because most individuals with hepatitis virus infection are
asymptomatic, the use of a questionnaire to exclude hepatitis
would be insufﬁcient. Second, we used mortality data rather
than incidence data as an endpoint. However, the prognosis
of liver cancer is generally poor: relative 5-year survival
rates were 21.2% to 27.1% from 1993–1996 to 2000–2002,
according to statistics by the Japan National Cancer Center,25
which means that most incident cases are detected as mortality
cases.25 Third, weight and height were self-reported in the
current study and were not validated by actual measurements.
However, a previous validation study of a Japanese population
indicated that self-reported weight and height strongly
correlated with previously measured weight and height: the
reported Pearson correlation coefﬁcients for men and women
were 0.979 and 0.998 for height and 0.961 and 0.959 for
weight, respectively, ie, the differences were immaterial.26
Fourth, weight at age 20 was also self-reported. However, 1
study found that long-term recall of past body weights was
reasonably accurate in Japanese adults27 and that people who
had experienced weight loss after age 25 years underestimated
their past weights, whereas those with stable weight or
weight gain overestimated them.27 Recall bias resulting in
misclassiﬁcation of weight changes would likely lead to
overestimation of real associations. Fifth, only 70% of the
present cases reported their weight at age 20 and at baseline.
However, any selection bias caused by missing data is unlikely
to affect the results because age (57.0 vs 58.2 years), baseline
BMI (22.8 vs 22.7 kg/m2), and other baseline variables were
similar between the included and excluded subjects.
In conclusion, underweight (BMI <18.5 kg/m2) and
overweight (BMI ≥25 kg/m2) in men without liver disease,
and weight gain (weight change ≥5 kg) after age 20 in women
with liver disease, were associated with increased mortality
from liver cancer. Higher BMI tended to be associated with
higher mortality from liver cancer among women and women
with a history of liver disease. Weight change was positively
associated with increased risk of liver cancer mortality in
women with or without liver disease.
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